VIII

Octapharma AG: Indirect comparison data indicate that personalised prophylaxis with Nuwiq® may lead to fewer patients with haemophilia A having bleeds than with other recombinant factor VIII products

Retrieved on: 
Tuesday, October 31, 2023
Haemophilia, Factor VIII, European Journal, PROPEL, PROTECT, Exercise, Georgetown University Medical Center, VIII, Georgetown Lombardi Comprehensive Cancer Center, Efmoroctocog alfa, Patient, Pharmaceutical industry, Dentistry

The analysis used data from prospective clinical trials of personalised prophylaxis in adults with severe haemophilia A.

Key Points: 
  • The analysis used data from prospective clinical trials of personalised prophylaxis in adults with severe haemophilia A.
    Dr Kessler commented, "This MAIC exercise provides important comparative data on the efficacy and consumption of various recombinant FVIII products in adults with haemophilia A on personalised prophylaxis.
  • The results can be considered by clinicians and patients when treatment decisions are being made."
  • MAICs are a way of comparing the efficacy of different medical interventions or products in the absence of head-to-head randomised trials3.
  • In addition, a short video summarising the results is available in the online version of the article.

Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA

Retrieved on: 
Wednesday, October 18, 2023
Q&A, American Institute, International Conference on Bioinformatics, Haemophilia, Therapy, RNA, Biotechnology, LNP, Congress, Liver, IL-6, Cytokine, Conference, American Institute of Chemical Engineers, VIII, RES, Mouse, European Society of Gene and Cell Therapy, Tissue, Cell, Gene, Webcast, Messenger, ESGCT, Generation, European Society of Clinical Microbiology and Infectious Diseases, Investment, Patient, NHP, DNA, Mobile phone, Vaccine, Moderna

CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company developing genetic medicines for people living with rare and prevalent diseases, today announced the development of a proprietary, novel DNA called immune-quiet DNA (iqDNA). iqDNA is an optimized variant of the company’s closed-ended DNA (ceDNA) that upon systemic administration with Generation Bio’s lipid nanoparticle (LNP) delivery has shown cytokine levels and tolerability comparable to chemically modified messenger RNA (mRNA) in mice and non-human primates (NHPs).

Key Points: 
  • Generation Bio’s non-viral genetic medicine platform aims to advance durable, redosable, and titratable therapies to reach potentially hundreds of millions of patients worldwide.
  • The company has made deep investments in its three proprietary platform technologies, comprising novel DNA cargos, rapid enzymatic synthesis (RES) manufacturing, and cell-targeted LNP (ctLNP) delivery.
  • The presentation will cover the development and progress of Generation Bio’s ctLNP platform, including its stealth and targeting delivery system.
  • Registration information for the webcast can be found on the Events page of Generation Bio’s investor website.

Global Cobalt Market Analysis Report 2023: Demand is Projected to Rise to 267.33 Kilotonnes by 2028 - DRC Holds the Largest Market Share, while Indonesia is Poised to be the Fastest-Growing Country - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 18, 2023
Technology, Batteries, Chemicals, Plastics, Manufacturing, Metal, Eramet, Renewable energy, EV, Chemical substance, Glencore, Battery, Form, ASM, Nickel, Electric vehicle, BASF, Cobalt, VIII, ESS, Growth, Transport, Democratic republic, General Motors, COVID-19, Lead, Recycling, Energy, EVS, Copper, GM, Mining, Pigment, Uranium mining, Electronics, DRC, EU

The global cobalt market mined supply stood at 205.30 kilotonnes in 2022.

Key Points: 
  • The global cobalt market mined supply stood at 205.30 kilotonnes in 2022.
  • Whereas, The cobalt market demand is projected to rise to 267.33 kilotonnes by 2028.
  • This would help to meet the growing demand for cobalt and stabilize the price of cobalt, resulting in market growth.
  • DRC currently holds the largest market share, while Indonesia is poised to be the fastest-growing region in the coming years.

Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A

Retrieved on: 
Monday, September 25, 2023
US Foods, Bleeding, MHLW, Factor VIII, European Medicines Agency, ABR, Quality of life, Haemophilia, Fast Track, Coordinated Specialty Care, Arthralgia, European Commission, Marketing, Breakthrough therapy, Orphan drug, Patient, Physician, Risk, VIII, Sanofi, Joint, MAA, FDA, Haemophilia A, Chronic pain, Headache, Food, Birth control, Pharmaceutical industry, Welfare, Health

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO®[Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein], a first-in-class, high-sustained factor VIII replacement therapy.

Key Points: 
  • The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO®[Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein], a first-in-class, high-sustained factor VIII replacement therapy.
  • ALTUVIIIO is indicated for control of bleeding tendency in patients with hemophilia A (factor VIII deficiency).
  • ALTUVIIIO was also recently approved by the Taiwan Food and Drug Administration for treatment of adults and children with hemophilia A on August 31, 2023.
  • The high-sustained factor activity levels will enable patients and physicians to reimagine living with hemophilia.

Henry VIII’s favourite fool – a new book draws a portrait of the man the Tudor court loved to laugh at

Retrieved on: 
Monday, September 25, 2023
Fool, Poverty, Ageing, Time Bandits, Ear, Noise, Tongue, VIII, Friends, William Shakespeare, Lace, Entertainment, Book, Film industry, Tudor

And yet, one figure who sailed on apparently effortlessly through Henry’s bloody later years and the equally violent reigns of his successors was Will Somers, the court fool.

Key Points: 
  • And yet, one figure who sailed on apparently effortlessly through Henry’s bloody later years and the equally violent reigns of his successors was Will Somers, the court fool.
  • Somers died peacefully under Queen Elizabeth I after a long and successful career at the Tudor court.
  • It is this survivor’s tale that the Swedish historian Peter Andersson set out to tell in Fool: In Search of Henry VIII’s Closest Man.
  • Anyone who wants to know about this oddly central figure in Tudor life will find Andersson’s book worthwhile.

The king’s pet

    • Neither of those things would be tolerated for a moment in a normal courtier, which is presumably the point.
    • He was, the account books tell us, only an intermittent presence at court, since presumably little foolery goes a long way.
    • As that suggests, he wasn’t there chiefly for his witty banter, but to be looked at, laughed at and mocked.
    • As Ian Holm’s Napoleon says in Terry Gilliam’s film Time Bandits: comedy is about “little things hitting each other”.

Nobody’s fool

    • Was he, they repeatedly asked, truly a “natural fool”, or was he an “artificial fool”?
    • Although Andersson’s book is heavy going at times, this central puzzle animates it and keeps the reader guessing to the end.
    • One day when the king was lamenting his poverty, Somers told him it was because he employed so many “frauditors, conveyors and deceivers”.
    • Was that play on the words “auditors, surveyors and receivers” something that someone had taught him, like teaching a parrot to swear?

Precision BioLogic's Factor VIII Deficient Plasma with VWF Now FDA-Cleared for Sale in U.S.

Retrieved on: 
Monday, September 18, 2023
Factor VIII, Haemophilia, Research, Biologic, ISTH, Von Willebrand factor, Plasma, VWF, Traction, Hemostasis, VIII, FDA, Vaccine, EU, NS

The latest in Precision BioLogic's family of factor deficient plasmas, CRYOcheck Factor VIII Deficient Plasma with VWF is intended for use in clinical laboratories to identify factor VIII (FVIII) deficiency in human plasma and aid in the management of hemophilia A.

Key Points: 
  • The latest in Precision BioLogic's family of factor deficient plasmas, CRYOcheck Factor VIII Deficient Plasma with VWF is intended for use in clinical laboratories to identify factor VIII (FVIII) deficiency in human plasma and aid in the management of hemophilia A.
  • CRYOcheck Factor VIII Deficient Plasma with VWF comes in a convenient frozen format, which eliminates reconstitution errors and reduces preparation time.
  • CRYOcheck Factor VIII Deficient Plasma with VWF launched in Canada, the EU, UK, Australia and New Zealand in 2021.
  • "CRYOcheck Factor VIII Deficient Plasma with VWF offers labs a readily available and reliable alternative to congenital FVIII deficient plasmas.

Allianz Trade Announces Sponsorship of U.S. Paralympian

Retrieved on: 
Wednesday, August 30, 2023
Professional Services, Sports, Olympics, Other Professional Services, Insurance, Finance, General Sports, Paralympic Games, Partnership, World championship, XI, IX, United States national team, Respect, VII, Allianz, VIII, Disease, Euler Hermes, Olympic, Paralympic movement in Tasmania, Mortality, 2016 Summer Paralympics, III, Trade, AA, VI, Bank

Allianz Trade in North America today announced that it has signed on to sponsor U.S. Paralympian Daniel Romanchuk.

Key Points: 
  • Allianz Trade in North America today announced that it has signed on to sponsor U.S. Paralympian Daniel Romanchuk.
  • “We’re proud to have Daniel as part of our Allianz Trade family; the perseverence he exhibits through his rigorous training and race schedule is something to be admired,” said James Daly, President and CEO, Allianz Trade Americas.
  • “Our team looks forward to supporting him throughout his journey to Paris 2024.”
    Romanchuk is a Baltimore native, where the Allianz Trade Americas Region headquarters is located.
  • This sponsorship complements Allianz being the Worldwide Insurance Partner of the Olympic and Paralympic Movements from 2021 through 2028.

Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 16, 2023
Good, ED95, Bromide, Bio, Drug discovery, Clinical trial, EMG, NMB, Research, Myasthenia gravis, Doctor of Philosophy, TI-68, Acquisition, Patent, Patient, IRB, VIII, Data, Plasma protein binding, Neuromuscular blocking agents, Intubation, FDA, Haemophilia A, IND, Three Months, Treatment, Pharmaceutical industry, Clothing, Cryptocurrency, Birth control, Haemophilia

MALVERN, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) --  Baudax Bio, Inc. (Nasdaq:BXRX) (“Baudax Bio” or the “Company”), is a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced results for the three and six months ended June 30, 2023 and provided a business update.

Key Points: 
  • “Our second quarter was a transformative period for Baudax Bio, during which we announced positive top-line results from our Phase 2 BX1000 trial and capped off with our acquisition of TeraImmune,” said Gerri Henwood, President and Chief Executive Officer of Baudax Bio.
  • The acquisition was unanimously approved by the Board of Directors of Baudax Bio and the Board of Directors of TeraImmune.
  • Financial Results for the Three Months Ended June 30, 2023
    As of June 30, 2023, Baudax Bio had cash and cash equivalents of $1.4 million.
  • Baudax Bio reported net loss from continuing operations of $(14.7) million, or $(4.08) per share, for the six months ended June 30, 2023.

Younger Generations: Key Drivers of the Global Blood Plasma Market in 2023 - Insights on Immunoglobulins, Coagulation Factors, and Albumin-derived Therapies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 15, 2023
Health, Other Health, Prevalence, Antibody, Hospital, Infection, DSM-IV codes, Ageing, Factor IX, Haemophilia, Multiple sclerosis, Plasma, Patient, Developed country, Application, VIII, Blood, Cancer, Conditional sentence, Growth, Immunodeficiency, Injury, Blood product, Hypogammaglobulinemia

By Type: The report splits the global blood plasma market into four different types: Immunoglobulin, Albumin, Coagulation Factors and Others.

Key Points: 
  • By Type: The report splits the global blood plasma market into four different types: Immunoglobulin, Albumin, Coagulation Factors and Others.
  • Immunoglobulin products are derived from blood plasma and are used to treat various medical conditions, including immune deficiencies, autoimmune diseases, and certain infections.
  • By Application: The global blood plasma market can be divided into four segments on the basis of application: Immunodeficiency Diseases, Hypogammaglobulinemia, Hemophilia and Other.
  • By End User: The report divides the global blood plasma market into three end users: Hospitals, Clinics and Others.

UNITE HERE Local 11 Blackstone Group Investor Alert: Hotel Workers Strike Blackstone-owned Southern California Hotels

Retrieved on: 
Wednesday, July 12, 2023
Public Policy, Government, Human Resources, Lodging, Environmental, Social and Governance (ESG), Travel, Labor, Professional Services, Advocacy Group Opinion, Blackstone, Blackstone Inc., Westin Bonaventure Hotel, VIII, Canal

Workers at the Fairfield and Aloft Los Angeles Airport hotels owned by affiliates of Blackstone Group are on strike as of July 10, 2023, joining the largest hotel workers’ strike in modern history.

Key Points: 
  • Workers at the Fairfield and Aloft Los Angeles Airport hotels owned by affiliates of Blackstone Group are on strike as of July 10, 2023, joining the largest hotel workers’ strike in modern history.
  • Blackstone Group investors should tell the firm to agree to a fair contract and put an end to the labor dispute as soon as possible.
  • Blackstone hotel workers are demanding a contract that provides wages, benefits and protections that allow them to live and provide for their families in Southern California.
  • Workers reached such an agreement with the largest hotel in Los Angeles, the Westin Bonaventure, on June 30, 2023.